Thrombophilia and retinal vascular occlusion

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1377-1384

  Glueck, Charles J ^a   Hutchins, Robert K ^b,c   Jurantee, Joel ^a   Khan, Zia ^a   Wang, Ping ^a  

^a JEWISH HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CINCINNATI EYE INSTITUTE   (United States)

Author keywords

Amaurosis fugax; Central retinal artery occlusion; Central retinal vein occlusion; Estrogen; Estrogen agonist; Retinal vascular occlusion; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 8; CONJUGATED ESTROGEN; CYANOCOBALAMIN; ESTROGEN; FOLIC ACID; GESTAGEN; HOMOCYSTEINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; ORAL CONTRACEPTIVE AGENT; PYRIDOXINE; TAMOXIFEN CITRATE; TESTOSTERONE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; FEMALE; FIBRINOLYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROTEIN S DEFICIENCY; RISK ASSESSMENT; RISK FACTOR; THROMBOPHILIA; TRANSITIONAL BLINDNESS;

EID: 84865809212     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S34627     Document Type: Article

References (66)

1. Sottilotta G, Oriana V, Latella C, et al. Role of hyperhomocystinemia in retinal vascular occlusive disease. Clin Appl Thromb Hemost. 2007;13(1):104-107.
2. Marcucci R, Sodi A, Giambene B, et al. Cardiovascular and thrombophilic risk factors in patients with retinal artery occlusion. Blood Coagul Fibrinolysis. 2007;18(4):321-326.
3. Sottilotta G, Siboni SM, Latella C, et al. Hyperhomocysteinemia and C677T MTHFR genotype in patients with retinal vein thrombosis. Clin Appl Thromb Hemost. 2010;16(5):549-553.
4. Kuo JZ, Lai CC, Ong FS, et al. Central retinal vein occlusion in a young Chinese population: risk factors and associated morbidity and mortality. Retina. 2010;30(3):479-484.
5. Marcucci R, Sofi F, Grifoni E, Sodi A, Prisco D. Retinal vein occlusions: a review for the internist. Intern Emerg Med. 2011;6(4):307-314.
6. Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Lang JE. Estrogen replacement therapy, thrombophilia, and atherothrombosis. Metabolism. 2002;51(6):724-732.
7. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med. 2003;349(15):1443-1450.
8. Viola MI, Meyer D, Kruger T. Association between clomiphene citrate and visual disturbances with special emphasis on central retinal vein occlusion: a review. Gynecol Obstet Invest. 2011;71(2):73-76.
9. Gorin MB, Costantino JP, Kulacoglu DN, et al. Is tamoxifen a risk factor for retinal vaso-occlusive disease? Retina. 2005;25(4):523-526.
10. Murray DC, Christopoulou D, Hero M. Combined central retinal vein occlusion and cilioretinal artery occlusion in a patient on hormone replacement therapy. Br J Ophthalmol. 2000;84(5):549-550.
11. Mayer H. A contribution about serious ophthalmic complications with oral contraceptives. Klin Monbl Augenheilkd. 1979;175(5):677-680. German.
12. Jaworek K. Case of central retinal vein thrombosis in a young woman treated with progesterone. Klin Oczna. 1976;46(1):75-78. Polish.
13. Leong KC, Tan PL. Central retinal vein thrombosis in a woman on contraceptive pills. Singapore Med J. 1974;15(2):156-157.
14. Güven D, Sayinalp N, Kalayci D, Dündar S, Hasiripi H. Risk factors in central retinal vein occlusion and activated protein C resistance. Eur J Ophthalmol. 1999;9(1):43-48.
15. Glueck CJ, Goldenberg N, Bell H, Golnik K, Wang P. Amaurosis fugax: associations with heritable thrombophilia. Clin Appl Thromb Hemost. 2005;11(3):235-241.
16. Glueck CJ, Golnik K, Ping W. Amaurosis fugax caused by heritable thrombophilia-hypofibrinolysis in cases without carotid atherosclerosis: thromboprophylaxis prevents subsequent transient monocular partial blindness. Clin Appl Thromb Hemost. 2007;13(2):124-129.
17. Roşca T. Methods of prevention of ischemic cerebral damages in patients with antiphospholipid antibodies. Oftalmologia. 2008;52(2): 72-76. Romanian.
18. Vastag O, Tornóczky J. Arterial occlusion in the ocular fundus induced by oral contraceptives. Orv Hetil. 1984;125(51):3121-3125. Hungarian.
19. Paufique L, Lequin M. Thrombosis of the retinal artery and oral contraceptives. Bull Soc Ophtalmol Fr. 1968;68(4):512-515. French.
20. Blade J, Darleguy P, Chanteau Y. Early thrombosis of the central retinal artery and oral contraceptives. Bull Soc Ophtalmol Fr. 1971;71(1):48-49. French.
21. Jampol LM, Isenberg SJ, Goldberg MF. Occlusive retinal arteriolitis with neovascularization. Am J Ophthalmol. 1976;81(5):583-589.
22. Gombos GM, Moreno DH, Bedrossian PB. Retinal vascular occlussion induced by oral contraceptives. Ann Ophthalmol. 1975;7(2):215-217.
23. Friedman S, Golan A, Shoenfeld A, Goldman J. Acute ophthalmologic complications during the use of oral contraceptives. Contraception. 1974;10(6):685-692.
24. Glueck CJ, Bell H, Vadlamani L, et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol. 1999;117(1):43-49.
25. Glueck CJ, Fontaine RN, Wang P. Interaction of heritable and estrogen-induced thrombophilia: possible etiologies for ischemic optic neuropathy and ischemic stroke. Thromb Haemost. 2001;85(2):256-259.
26. Glueck CJ, Hutchins RK, Khan A, Bains PS, Khan N, Wang P. Successful anticoagulation for bilateral central retinal vein occlusion. Clin Chim Acta. 2011;412(11-12):1165-1166.
27. Glueck CJ, Ping W, Hutchins R, Petersen MR, Golnik K. Ocular vascular thrombotic events: central retinal vein and central retinal artery occlusions. Clin Appl Thromb Hemost. 2008;14(3):286-294.
28. Glueck CJ, Wang P, Bell H, Rangaraj V, Goldenberg N. Nonarteritic anterior ischemic optic neuropathy: associations with homozygosity for the C677T methylenetetrahydrofolate reductase mutation. J Lab Clin Med. 2004;143(3):184-192.
29. Glueck CJ, Wang P, Bell H, Rangaraj V, Goldenberg N. Associations of thrombophilia, hypofibrinolysis, and retinal vein occlusion. Clin Appl Thromb Hemost. 2005;11(4):375-389.
30. Cheung N, Klein R, Wang JJ, et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci. 2008;49(10):4297-4302.
31. Greiner K, Hafner G, Dick B, Peetz D, Prellwitz W, Pfeiffer N. Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol. 1999;128(1):69-74.
32. Larsson J. Central retinal artery occlusion in a patient homozygous for factor V Leiden. Am J Ophthalmol. 2000;129(6):816-817.
33. Larsson J, Hillarp A, Olafsdottir E, Bauer B. Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta Ophthalmol Scand. 1999;77(6):634-637.
34. Hansen L, Kristensen HL, Bek T, Ingerslev J. Markers of thrombophilia in retinal vein thrombosis. Acta Ophthalmol Scand. 2000;78(5): 523-526.
35. Scott JA, Arnold JJ, Currie JM, et al. No excess of factor V:Q506genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients. Ophthalmologica. 2001;215(3):217-221.
36. Lipid Research Clinics. Population Studies Data Book. Vol 1. The Prevalence Study. NIH publication no 80-1527. Bethesda, MD; National Institutes of Health; 1980.
37. National Center for Health Statistics. Plan and operation of the third National Health and Nutrition Survey, 1988-1994. Series 1: programs and collection procedures. Vital Health Stat 1. 1994;32:1-407.
38. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21(4):518-524.
39. Balasa VV, Gruppo RA, Glueck CJ, et al. The relationship of mutations in the MTHFR, prothrombin, and PAI-1genes to plasma levels of homocysteine, prothrombin, and PAI-1in children and adults. Thromb Haemost. 1999;81(5):739-744.
40. Glueck CJ, Wang P, Bornovali S, Goldenberg N, Sieve L. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism. 2003;52(12):1627-1632.
41. Glueck CJ, Iyengar S, Goldenberg N, Smith LS, Wang P. Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med. 2003;142(1):35-45.
42. Glueck CJ, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost. 2004;10(4):323-334.
43. Glueck CJ, Pranikoff J, Aregawi D, et al. The factor V Leiden mutation, high factor VIII, and high plasminogen activator inhibitor activity: etiologies for sporadic miscarriage. Metabolism. 2005;54(10):1345-1349.
44. Glueck CJ, Aregawi D, Goldenberg N, Golnik KC, Sieve L, Wang P. Idiopathic intracranial hypertension, polycystic-ovary syndrome, and thrombophilia. J Lab Clin Med. 2005;145(2):72-82.
45. Glueck CJ, Glueck HI, Tracy T, Speirs J, McCray C, Stroop D. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism. 1993;42(2):236-246.
46. Glueck CJ, Freiberg RA, Fontaine RN, Tracy T, Wang P. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res. 2001;386: 19-33.
47. Abu El-Asrar AM, Abdel Gader AG, Al-Amro SA, Al-Attas OS. Hyperhomocysteinemia and retinal vascular occlusive disease. Eur J Ophthalmol. 2002;12(6):495-500.
48. Weger M, Stanger O, Deutschmann H, et al. Hyperhomocyst(e)-inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002;240(4):286-290.
49. Ferrazzi P, Di Micco P, Quaglia I, et al. Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B 12in patients with retinal vein occlusion. Thromb J. 2005;3:13.
50. Lattanzio R, Sampietro F, Ramoni A, Fattorini A, Brancato R, D'Angelo A. Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion. Retina. 2006;26(1):65-70.
51. Sodi A, Giambene B, Marcucci R, et al. Atherosclerotic and thrombophilic risk factors in patients with recurrent central retinal vein occlusion. Eur J Ophthalmol. 2008;18(2):233-238.
52. Sofi F, Marcucci R, Bolli P, et al. Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels. Atherosclerosis. 2008;198(1):223-227.
53. Bick RL. Antiphospholipid thrombosis syndromes. Hematol Oncol Clin North Am. 2003;17(1):115-147.
54. Faude F, Faude S, Siegemund A, Wiedemann P. Factor VIII activity in patients with central retinal vein occlusion in comparison to patients with a history of pelvic and lower limb venous thrombosis and a healthy control group [in German]. Klin Monbl Augenheilkd. 2004;221(10):862-866.
55. Cahill M, Karabatzaki M, Meleady R, et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol. 2000;84(2):154-157.
56. Coroi M, Bontas E, Defranceschi M, Bartos D, Dorobantu M. Ocular manifestations of antiphospholipid (Hughes)' syndrome-minor features? Oftalmologia. 2007;51(3):16-22.
57. Cacciapuoti F. Some considerations about the hypercoagulable states and their treatments. Blood Coagul Fibrinolysis. 2011;22(3):155-159.
58. den Heijer M, Brouwer IA, Bos GM, et al. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol. 1998;18(3):356-361.
59. Green TJ, Skeaff CM, McMahon JA, et al. Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations. Br J Nutr. 2010;103(11):1629-1634.
60. Hoţoleanu C, Porojan-Iuga M, Rusu ML, Andercou A. Hyperhomocysteinemia: clinical and therapeutical involvement in venous thrombosis. Rom J Intern Med. 2007;45(2):159-164.
61. Di Minno MN, Tremoli E, Coppola A, Lupoli R, Di Minno G. Homocysteine and arterial thrombosis: challenge and opportunity. Thromb Haemost. 2010;103(5):942-961.
62. Ray JG, Kearon C, Yi Q, et al. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med. 2007;146(11):761-767.
63. Sodi A, Giambene B, Marcucci R, et al. Atherosclerotic and thrombophilic risk factors in patients with ischemic central retinal vein occlusion. Retina. 2011;31(4):724-729.
64. Salomon O, Huna-Baron R, Kurtz S, et al. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 1999;106(4):739-742.
65. DeSancho MT, Dorff T, Rand JH. Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy. Blood Coagul Fibrinolysis. 2010;21(6):534-538.
66. Douketis JD, Julian JA, Crowther MA, et al. The effect of prothrombotic blood abnormalities on risk of deep vein thrombosis in users of hormone replacement therapy: a prospective case-control study. Clin Appl Thromb Hemost. 2011;17(6):E106-E113.